Instituto Universitario de Investigación en Neuroquímica
Ikastegia/Institutua
Instituto de Química Médica
Madrid, EspañaInstituto de Química Médica -ko ikertzaileekin lankidetzan egindako argitalpenak (34)
2024
-
The CB1 receptor interacts with cereblon and drives cereblon deficiency-associated memory shortfalls
EMBO Molecular Medicine, Vol. 16, Núm. 4, pp. 755-783
2023
-
Thienopyrimidine Derivatives as GPR55 Receptor Antagonists: Insight into Structure-Activity Relationship
ACS Medicinal Chemistry Letters, Vol. 14, Núm. 1, pp. 18-25
2022
-
Editorial: Cannabinoids as potential treatment for neurological diseases
Frontiers in Neuroscience
-
IQM-PC332, a Novel DREAM Ligand with Antinociceptive Effect on Peripheral Nerve Injury-Induced Pain
International Journal of Molecular Sciences, Vol. 23, Núm. 4
-
β-Lactam TRPM8 Antagonist RGM8-51 Displays Antinociceptive Activity in Different Animal Models
International Journal of Molecular Sciences, Vol. 23, Núm. 5
2021
-
Preclinical investigation in neuroprotective effects of the gpr55 Ligand VCE-006.1 in experimental models of Parkinson’s disease and amyotrophic lateral sclerosis
Molecules, Vol. 26, Núm. 24
-
Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis
European Journal of Medicinal Chemistry, Vol. 210
2019
-
11PS04 is a new chemical entity identified by microRNA-based biosensing with promising therapeutic potential against cancer stem cells
Scientific Reports, Vol. 9, Núm. 1
-
Identification of IQM-266, a novel DREAM ligand that modulates KV4 currents
Frontiers in Molecular Neuroscience, Vol. 12
2018
-
Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors
European Journal of Medicinal Chemistry, Vol. 145, pp. 431-444
2017
-
Corrigendum to “Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile” [Pharmacol. Res. (2016) 110(2016) (205–215)] (S1043661816302080) (10.1016/j.phrs.2016.03.021)
Pharmacological Research
-
New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking
European Journal of Medicinal Chemistry, Vol. 127, pp. 398-412
2016
-
Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile
Pharmacological Research, Vol. 110, pp. 205-215
-
Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis
Journal of Medicinal Chemistry, Vol. 59, Núm. 14, pp. 6753-6771
-
Exploring the Benzimidazole Ring as a Substitution for Indole in Cannabinoid Allosteric Modulators
Cannabis and Cannabinoid Research, Vol. 1, Núm. 1, pp. 196-201
-
Identification of Novel GPR55 Modulators Using Cell-Impedance-Based Label-Free Technology
Journal of Medicinal Chemistry, Vol. 59, Núm. 5, pp. 1840-1853
-
Targeting cannabinoid CB2 receptors in the central nervous system. Medicinal chemistry approaches with focus on neurodegenerative disorders
Frontiers in Neuroscience, Vol. 10, Núm. SEP
2015
-
Selective, nontoxic CB2 cannabinoid o-quinone with in vivo activity against triple-negative breast cancer
Journal of Medicinal Chemistry, Vol. 58, Núm. 5, pp. 2256-2264
-
Synthesis, pharmacological evaluation and docking studies of pyrrole structure-based CB2 receptor antagonists
European Journal of Medicinal Chemistry, Vol. 101, pp. 651-667
-
The melatonin- N,N-dibenzyl(N-methyl)amine hybrid ITH91/IQM157 affords neuroprotection in an in vitro Alzheimer's model via hemo-oxygenase-1 induction
ACS Chemical Neuroscience, Vol. 6, Núm. 2, pp. 288-296